BioCryst [BCRX] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

BioCryst

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: BioCryst wins in 11 metrics, Haleon Plc - ADR wins in 8 metrics, with 0 ties. BioCryst appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBioCrystHaleon Plc - ADRBetter
P/E Ratio (TTM)-16.6319.89BioCryst
Price-to-Book Ratio-3.555.07BioCryst
Debt-to-Equity Ratio-1.7553.41BioCryst
PEG Ratio0.1221.31BioCryst
EV/EBITDA33.8433.80Haleon Plc - ADR
Profit Margin (TTM)-6.41%13.81%Haleon Plc - ADR
Operating Margin (TTM)18.23%22.21%Haleon Plc - ADR
EBITDA Margin (TTM)18.23%22.21%Haleon Plc - ADR
Return on Equity18.68%9.38%BioCryst
Return on Assets (TTM)7.46%4.61%BioCryst
Free Cash Flow (TTM)$-53.14M$2.67BHaleon Plc - ADR
Dividend YieldN/A1.63%N/A
1-Year Return-5.52%-12.54%BioCryst
Price-to-Sales Ratio (TTM)2.693.62BioCryst
Enterprise Value$1.98B$119.36BHaleon Plc - ADR
EV/Revenue Ratio3.558.05BioCryst
Gross Profit Margin (TTM)98.29%55.38%BioCryst
Revenue per Share (TTM)$3$2BioCryst
Earnings per Share (Diluted)$-0.18$0.45Haleon Plc - ADR
Beta (Stock Volatility)1.050.23Haleon Plc - ADR
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

BioCryst vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

BioCryst
Haleon Plc - ADR
BioCryst Stock Overview | Haleon Plc - ADR Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BioCryst-1.82%-7.02%-14.29%-19.86%3.39%-10.34%
Haleon Plc - ADR-1.79%-0.57%-9.75%-13.40%-5.18%-6.89%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BioCryst-5.52%-48.12%82.34%-20.59%39.84%-58.09%
Haleon Plc - ADR-12.54%45.53%18.62%18.62%18.62%18.62%

News Based Sentiment: BioCryst vs Haleon Plc - ADR

BioCryst

News based Sentiment: POSITIVE

BioCryst's strategic sale of its European business and subsequent debt reduction are significant developments that position the company for stronger financial performance and focused growth in the U.S. market. While an 'In-Line' rating and oversold territory suggest caution, the overall narrative is positive due to the proactive steps taken by management.

View BioCryst News Sentiment Analysis

Haleon Plc - ADR

News sentiment data is not available for Haleon Plc - ADR at this time.

Performance & Financial Health Analysis: BioCryst vs Haleon Plc - ADR

MetricBCRXHLN
Market Information
Market Cap i$1.55B$41.44B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i2,671,4438,861,440
90 Day Avg. Volume i2,651,8649,003,930
Last Close$7.02$8.79
52 Week Range$6.02 - $11.31$8.71 - $11.42
% from 52W High-37.93%-23.03%
All-Time High$37.25 (Mar 06, 2000)$11.42 (Jun 02, 2025)
% from All-Time High-81.15%-23.03%
Growth Metrics
Quarterly Revenue Growth0.49%-0.01%
Quarterly Earnings Growth0.49%0.33%
Financial Health
Profit Margin (TTM) i-0.06%0.14%
Operating Margin (TTM) i0.18%0.22%
Return on Equity (TTM) i0.19%0.09%
Debt to Equity (MRQ) i-1.7553.41
Cash & Liquidity
Book Value per Share (MRQ)$-2.01$1.77
Cash per Share (MRQ)$1.24$0.08
Operating Cash Flow (TTM) i$16.82M$3.34B
Levered Free Cash Flow (TTM) i$53.98M$2.59B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: BioCryst vs Haleon Plc - ADR

MetricBCRXHLN
Price Ratios
P/E Ratio (TTM) i-16.6319.89
Forward P/E i-178.7521.31
PEG Ratio i0.1221.31
Price to Sales (TTM) i2.693.62
Price to Book (MRQ) i-3.555.07
Market Capitalization
Market Capitalization i$1.55B$41.44B
Enterprise Value i$1.98B$119.36B
Enterprise Value Metrics
Enterprise to Revenue i3.558.05
Enterprise to EBITDA i33.8433.80
Risk & Other Metrics
Beta i1.050.23
Book Value per Share (MRQ) i$-2.01$1.77

Financial Statements Comparison: BioCryst vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BCRXHLN
Revenue/Sales i$145.53M$3.71B
Cost of Goods Sold i$4.57M$1.66B
Gross Profit i$140.97M$2.06B
Research & Development i$37.27M$104.91M
Operating Income (EBIT) i$21.23M$470.76M
EBITDA i$24.58M$486.90M
Pre-Tax Income i$758,000$387.37M
Income Tax i$726,000$88.77M
Net Income (Profit) i$32,000$298.60M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BCRXHLN
Cash & Equivalents i$105.19M$909.24M
Total Current Assets i$409.98M$5.57B
Total Current Liabilities i$139.86M$6.41B
Long-Term Debt i$792.12M$10.28B
Total Shareholders Equity i$-451.93M$21.52B
Retained Earnings i$-1.77B$36.67B
Property, Plant & Equipment i$19.58M$2.51B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BCRXHLN
Operating Cash Flow i$21.14MN/A
Capital Expenditures i$-143,000N/A
Free Cash Flow i$-27.66MN/A
Debt Repayment i$-516,000N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBCRXHLN
Shares Short i28.32M15.71M
Short Ratio i12.151.93
Short % of Float i0.14%0.00%
Average Daily Volume (10 Day) i2,671,4438,861,440
Average Daily Volume (90 Day) i2,651,8649,003,930
Shares Outstanding i208.54M12.27B
Float Shares i195.52M8.99B
% Held by Insiders i0.01%0.00%
% Held by Institutions i0.99%0.13%

Dividend Analysis & Yield Comparison: BioCryst vs Haleon Plc - ADR

MetricBCRXHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025